Johnson & Johnson is partnering with Insuline Medical to register and distribute the Israeli company's InsuPad for promoting optimal absorption of insulin in diabetics by warming their injection site.
India's National Pharmaceutical Pricing Authority has told drugmakers that failure to hand in drug price and sales data by next week is not an option.
China's market for medical devices is expected to pass Japan's this year to become the world's second-largest, topped only by the United States. A consulting firm forecast China's market would pass the $55 billion mark this year.
Sanofi bought control of Shantha Biotechnics in 2009 as a way to access low-cost vaccine manufacturing in India. Now the drugmaker will use the subsidiary to expand insulin production.
India's Central Drugs Standard Control Organization wants to tweak the rules on its presubmission process with agency staff and experts.
The Chinese Pharmacopoeia Commission and Waters launched their Joint Open Laboratory on Jan. 28 in Beijing that aims to produce the first official compendium of drugs.
Don't look for any Trans-Pacific Partnership agreement on patent lengths for biologics this year. That was the message delivered at a congressional hearing on Tuesday.
Lupin is now allowed to sell off up to 49% of the company--if it decides it wants to--in a deal or deals that could be worth more than $1 billion. At Lupin's request, India's Cabinet decided to raise the cap on foreign investment in the company; previously, Lupin was allowed to sell up to a 33% stake.
Serum Institute of India, which has a history of undercutting its competition in the vaccine sphere, is expanding this undercutting game to HPV. Its low-cost competitor to Merck's Gardasil could hit the market in late 2018 at one-third the price.
European regulators have joined the FDA in suggesting joint plant inspections and training with their Indian counterparts. The offers come as India's industry has lost status in recent years as the FDA and other countries have banned Indian plants from shipping to the U.S. and Europe over quality and data-integrity issues.